MDXR MEDICAL EXERCISE INC.
Services-Health Services · OTC · SEC CIK 2001249 · Fiscal year ends 03/31
Financial factors as of 2025-03-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin65.6%
Operating margin65.6%
Net margin-25,578.4%
FCF margin-15,061.5%
EBITDA margin953.8%
Returns
ROE—
ROA-507.2%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets203.1%
Debt / equity—
Current ratio0.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.58x
Accruals ratio-214.5%
Payout ratio—
Capex / revenue299.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q3*2024-12-31 | 2025Q2*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1,000 | — | — | — | — | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | — | $0 | $0 | $0 |
| Gross profit | $1,000 | — | — | — | — | $0 | $0 | $0 |
| SG&A expense | — | — | $18,882 | $76,497 | $61,378 | $72,864 | $33,241 | $46,377 |
| Operating income | -$52,769 | -$42,397 | -$25,823 | -$83,852 | -$70,291 | $264,631 | -$141,207 | -$61,923 |
| Pretax income | -$52,666 | -$45,875 | -$25,823 | -$84,719 | -$70,291 | -$67,592 | -$141,207 | -$61,534 |
| Net income | -$52,666 | -$45,875 | -$25,823 | -$84,719 | -$70,291 | -$67,592 | -$141,207 | -$61,534 |
| EBITDA | -$52,227 | -$40,661 | -$23,882 | -$81,674 | -$67,410 | $267,462 | -$138,357 | -$58,979 |
| EPS (basic) | 0.00 | — | — | -0.01 | -0.01 | — | -0.01 | -0.01 |
| EPS (diluted) | 0.00 | — | — | -0.01 | -0.01 | — | -0.01 | -0.01 |
| Weighted avg. shares (diluted) | 13.33M | — | 12.37M | 12.33M | 12.29M | — | 12.22M | 12.17M |
| Balance sheet | ||||||||
| Cash & equivalents | $3,089 | $43,449 | $40,549 | $23,358 | $3,791 | $450 | $7,993 | $12,257 |
| Receivables | $1,000 | — | — | — | — | — | — | — |
| Current assets | $14,089 | $43,449 | $40,549 | $23,358 | $3,791 | $450 | — | — |
| PP&E, net | — | $15,924 | $40,039 | $41,273 | $57,629 | $59,903 | — | — |
| Intangibles | $2,626 | $1,957 | $4,992 | $4,874 | $5,201 | $4,908 | — | — |
| Total assets | $16,715 | $61,330 | $85,580 | $69,505 | $66,621 | $65,261 | — | — |
| Current liabilities | $252,888 | $244,837 | $223,212 | $281,314 | $193,711 | $132,560 | — | — |
| Total liabilities | $252,888 | $244,837 | $223,212 | $281,314 | $193,711 | $132,560 | — | — |
| Shareholders' equity | -$236,173 | -$183,507 | -$137,632 | -$211,809 | -$127,090 | -$67,299 | -$6 | -$64,500 |
| Shares outstanding | 13.33M | 13.33M | 13.33M | 12.33M | 12.33M | 12.22M | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$46,722 | -$17,536 | -$76,791 | -$21,841 | -$78,583 | -$46,597 | -$41,441 | -$37,137 |
| Capital expenditure | — | — | — | — | — | $0 | $0 | $0 |
| Free cash flow | — | — | — | — | — | -$46,597 | -$41,441 | -$37,137 |
| Investing cash flow | $6,362 | $21,936 | -$825 | $13,638 | -$900 | $0 | -$650 | $3,301 |
| Financing cash flow | — | -$1,500 | $94,807 | $27,770 | $82,824 | $39,054 | $37,827 | $40,256 |
| Depreciation & amortization | $542 | $1,736 | $1,941 | $2,178 | $2,881 | $2,831 | $2,850 | $2,944 |
| Stock-based compensation | — | $0 | $0 | $0 | $2,000 | $0 | — | — |
Free plan shows the latest 8 periods; Pro shows all 9 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.